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ABSTRACT
HSP70 connects multiple signaling pathways that work synergistically to protect 
tumor cells from death by proteotoxic stress and represents a possible target to 
establish a new approach for multiple myeloma treatment. Therefore, bioluminescent 
cell lines RPMI8226-LUC-PURO and U266-LUC-PURO were treated with HSP70 
(VER155008) and/or proteasome (bortezomib) inhibitors and immunodeficient mice 
were used for subcutaneous xenograft models to evaluate tumor growth reduction 
and tumor growth inhibition after treatment. Bioluminescence imaging was used to 
follow tumor response. Treatment with bortezomib showed ~60% of late apoptosis 
in RPMI8226-LUC-PURO (without additional benefit of VER155008 in this cell 
line). However, U266-LUC-PURO showed ~60% of cell death after treatment with 
VER155008 (alone or with bortezomib). RPMI8226-LUC-PURO xenograft presented 
tumor reduction by bioluminescence imaging after treatment with bortezomib, 
VER155008 or drug combination compared to controls. Treatment with bortezomib, 
alone or combined with VER155008, showed inhibition of tumor growth assessed by 
bioluminescence imaging after one week in both RPMI8226-LUC-PURO and U266-LUC-
PURO cell lines when compared to controls. In conclusion, our study shows that the 
combination of proteasome and HSP70 inhibitors induced cell death in tumor cells in 
vitro (late apoptosis induction) and in vivo (inhibition of tumor growth) with special 
benefit in U266-LUC-PURO, bearing 17p deletion. 
INTRODUCTION
Multiple myeloma (MM) is a lymphoid malignancy 
that represents 1% of all cancer cases and 13% of 
hematological neoplasms and still remains an incurable 
disease [1]. Even with an aggressive therapy, including 
immunomodulatory drugs (thalidomide, lenalidomide, 
pomalidomide), proteasome inhibitors (bortezomib, 
carfilzomib) and autologous transplant, survival of high risk 
MM patients is still poor [2–5]. Cytogenetics is one of the 
most important prognostic factors in MM and, according to 
current guidelines, patients with at least one of the following 
features at diagnosis, such as deletion of 17p, t(14;16) or 
t(14;20) detected by FISH analysis, have high risk MM [6].
Felix et al. (2009) [7] identified differentially 
expressed genes in normal and MM patient’s plasma 
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cells using Serial Analysis of Gene Expression (SAGE) 
and real time PCR (qPCR) validation. One of these 
genes, P53CSV/TRIAP1 (TP53 regulated inhibitor of 
apoptosis 1), was overexpressed in more than 90% of 
MM cases. TRIAP1 activates apoptotic pathways through 
interaction with HSP70, preventing APAF-1 (apoptosis 
protease activating factor 1), cytochrome c, and caspase-9 
apoptosome complex formation [8, 9]. Overexpression 
of HSP70 may provide a selective advantage for tumor 
cell survival due in part to its ability to inhibit cell death 
through APAF-1 and caspase 9 [10].
HSP70 activates protein homeostasis, one of the 
essential mechanisms for myeloma cell survival, avoiding 
tumor death caused by intracellular accumulation of 
abnormal immunoglobulin, also known as monoclonal 
component [11]. Thus, some metabolic pathways, 
including HSP70 and its members, ubiquitin-proteasome 
pathway and cellular stress pathways, such as unfolded 
protein response (UPR) and autophagy,  will contribute 
to the ability of neoplastic cells to adapt to the stress 
caused by immunoglobulin overload in the endoplasmic 
reticulum (ER). Since these pathways are used by tumor 
cells to ensure their survival, they can also be considered 
attractive therapeutic targets [12–14].
The HSP70 family is composed by 13 members of 
highly conserved proteins. The members better known 
for their cellular functions are: HSPA1A and HSPA1B 
(referred together as HSP70 or HSP72), HSPA5 (also 
known as BIP), HSPA8 (also known as HSC70), and 
HSPA9. They are involved in protein homeostasis and 
synthesis, folding of misfolded proteins (HSPA1A, 
HSPA1B an HSPA5), solubilization of protein aggregates, 
protein degradation through proteasome pathway and 
autophagy (HSPA1A, HSPA1B and HSPA8) [10, 15].
Evidences show that HSP70 is overexpressed in 
many types of cancer  and that high levels of this chaperone 
are linked with high tumor grade and/or poor prognosis. 
Inhibition of HSP72 and HCS70 simultaneously by 
shRNAs silencing resulted in retention of light chain 
immunoglobulins in myeloma cell lines (RPMI-8226 and 
KMS-11), causing proteotoxic stress and interfering with 
cell growth and survival [11, 16, 17, 18].  
Since several studies have proved that tumor cells 
(and not normal cells) present high levels of HSP70, which 
is involved in several mechanisms of protein homeostasis, 
the use of a HSP70 inhibitor could make tumor cells 
more sensitive to proteasome inhibitors and prevent the 
functioning of the proteasome and related pathways [10, 
19].
Clinical studies have tested HSP90 inhibitors 
combined with bortezomib in MM, but there is no 
evidence of clinical trials using HSP70 inhibitors in 
combination with bortezomib. [20] Therefore, the aim 
of this study is to explore the potential of HSP70 as a 
target in MM, through in vitro and in vivo analyses using 
proteasome and HSP70 inhibitors.
RESULTS 
RPMI8226-LUC-PURO and U266-LUC-PURO cell 
lines express HSP70 family genes (HSPA1A/ HSPA1B, 
HSPA5 and HSPA8), UPR gene XBP-1 and autophagy 
related gene Beclin-1. There was no difference in gene 
expression when bioluminescent and wild type cell lines 
were compared (Figure 1). HSP70 protein expression was 
also evaluated comparing bioluminescent and wild type 
cell lines:  there was no statistically significant difference 
in protein expression for both cell lines after luciferase 
gene transduction (Figure 2). 
Treatment with bortezomib and VER155008 (50 μM 
and 80 μM), isolated or combined, resulted in increased 
expression of HSPA1A/HSPA1B in RPMI8226-LUC-
PURO. RPMI8226-LUC-PURO also showed increased 
expression of HSPA5 and XBP-1 after treatment with 
VER155008 (50 μM) (Figure 3A). U266-LUC-PURO, 
treated with bortezomib, VER155008 (50μM and 80μM), 
isolated or combined, responded with increased expression 
of HSPA1A/HSPA1B. There was no statistically significant 
difference in the expression of other analyzed genes, in 
comparison to untreated cell line (Figure 3B). Therefore, 
both cell lines treated with bortezomib, VER155008 (50 
μM and 80 μM), isolated or combined, responded with 
increased expression of HSPA1A/HSPA1B.
In vitro studies with RPMI8226-LUC-PURO 
showed difference in the percentage of cells in apoptosis, 
over time. There was statistically significant increase in 
cell death after treatment with bortezomib when compared 
to controls (p < 0.001). Treatment with VER155008 
showed a statistically significant difference in cell death 
when compared to controls (p < 0.001). However, none 
of the above approaches using VER155008, alone or in 
combination, showed better response comparing with 
bortezomib alone in this cell line (60% of late apoptosis 
after 48 hours) (Figure 4A). 
U266-LUC-PURO showed good results with 
all treatments when compared to untreated cell line at 
24 and 48 hours (p < 0.001) (except for VER155008 
concentration 50μM in 24 hours). The percentage of 
cell death was higher in U266-LUC-PURO treated with 
VER155008 (50 μM) alone, or treated with VER155008 
(80 μM) alone or combined with bortezomib, showing at 
least 60% of cell death, after 48 hours (Two-way ANOVA, 
with Bonferroni post-test) (Figure 4B). 
After BLI analyses, in vivo model #1 showed 
RPMI8226-LUC-PURO tumor reduction in all mice 
treated with bortezomib, VER155008 or drug combination 
compared to control group (Figure 5A). Histological 
analysis from tumors (positive for lambda light chain, 
Figure 5C) of control mice exhibited a large amount of 
tumor cells (Figure 5B), whereas the evaluation of the 
histological sample of mice treated with bortezomib and 
VER155008 combination demonstrated apoptotic cells 
areas and coagulative necrosis that may correspond to the 
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results of bioluminescence (cold areas) (Figures 5D and 
5E). Expression of HSP70 was reduced in mice treated 
with all drugs, but it was statistically significant when 
VER155008 was compared to controls. Beclin-1 showed 
increased expression in mice treated with bortezomib 
compared to controls. VER155008 plus bortezomib 
combination was also  able to increase Beclin-1 expression 
when compared to VER155008 alone. In mice treated 
with VER155008, isolated or combined with bortezomib, 
expression of XBP-1s showed increased band intensity 
when compared to controls (Figure 6). Although the 
individual results are not homogeneous in all groups 
for tested proteins, graph bars represent protein relative 
expression, normalized with α/β tubulin, using four 
replicates.
In in vivo model #2,  instead of treating tumors 
after growth, we treated mice at the same time when 
cell lines were transplanted. We used RPMI8226-LUC-
PURO in the right flank and U266-LUC-PURO in the 
left flank to compare the behavior of both cell lines in the 
same mice. There was inhibition (or incipient growth) of 
tumor growth after treatment with bortezomib, isolated or 
combined with VER155008 assessed by BLI (Figure 7) 
after one week, for both cell lines when compared to the 
control group (Figure 8). Treatment with either bortezomib 
or VER155008 (isolated or combined) increased mice 
survival when compared to control group (death of two 
mice during monitoring), but the difference was not 
significant (Figure 9). 
DISCUSSION
Since HSP70 connects multiple signaling pathways 
that work synergistically to protect tumor cells from 
death by proteotoxic stress, it can represent a key role to 
establish a new approach for MM treatment. In this study, 
we evaluated the combination of a proteasome inhibitor 
(bortezomib) with a HSP70 inhibitor (VER155008) to 
understand how pathways related to protein homeostasis 
behave (heat shock proteins, UPR, ubiquitin-proteasome 
system and autophagy) when we interfere in two important 
processes for myeloma cells survival. Our study shows 
Figure 1: Expression profile of HSPA1A/HSPA5, HSPA5, HSPA8, XBP-1 and Beclin-1 genes by real-time quantitative 
PCR in RPMI8226 (WT) versus RPMI8226-LUC-PURO cell lines. (A) and (B) U266 (WT) versus U266-LUC-PURO cell lines. 
Relative expression was performed using 2-ΔΔCt formula and β-actin housekeeping gene. The analyses were done in triplicates. X axis: 
Genes; Y axis: fold change value. There was no statistically significant difference in the expression of all genes when comparing the two 
cell lines, with or without transduction with luciferase gene (p > 0.05). One-Way ANOVA, with Bonferroni’s post -test.  
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that combination of proteasome and HSP70 inhibitors 
induced cell death in tumor cells in vitro (late apoptosis 
induction) and in vivo (inhibition of tumor growth).
The rationale for our study was also used by 
Braunstein et al. (2011) [19]. The study demonstrated that 
the combination of MAL3-101, a HSP70 inhibitor, with a 
proteasome inhibitor (MG-132) may reduce the resistance 
of myeloma cells to proteasome inhibitors. In our study, 
we used two multiple myeloma cell lines recognized for 
the resistance or sensitivity to bortezomib (U266 and 
RPMI8226, respectively), in an attempt to confirm this 
action [19, 28]. 
In addition to exploring the role of HSP70 family 
in MM, our study showed how mechanisms related to 
protein homeostasis behave after inhibition of HSP70 and 
ubiquitin proteasome pathway, through evaluation of XBP-
1 and Beclin-1. 
RPMI8226-LUC-PURO and U266-LUC-PURO cell 
lines express HSP70 family genes (HSPA1A/ HSPA1B, 
HSPA5 and HSPA8), UPR gene XBP-1 and autophagy 
related gene Beclin-1 and there was no difference in gene 
expression when bioluminescent and wild type cell lines 
were compared, making the bioluminescent cell suitable 
for this study. Additionally, HSP70 protein expression 
was similar in bioluminescent and wild type cells by 
Western Blotting analysis. Protein bands were quantified 
by densitometry and showed no statistically significant 
difference between bioluminescent and wild type cells 
(Figure 2), confirming qPCR results. 
HSPA1A/HSPA1B showed increased expression 
when both bioluminescent cell lines were treated 
with bortezomib for 24 hours (isolated or associated 
with VER155008), suggesting that the inhibition of 
the proteasome - which acts to degrade and eliminate 
ubiquitinated proteins - by bortezomib requires intense 
activity of HSP70 as a compensation mechanism to avoid 
proteotoxic stress and cell death [29]. The isolated use 
of VER155008 at concentrations of 50μM and 80μM, 
for both cell lines, also led to a statistically significant 
increase in HSPA1A/HSPA1B expression, suggesting 
that competitive inhibition of the HSP70 binding site by 
VER155008 should also result in an increased expression 
of these genes as a compensation mechanism after 
treatment, which induce cellular stress. HSPA1A/HSPA1B 
and HSPA8 members share 85% sequence homology, and 
are considered to have compensatory roles [11, 15].
Figure 2: (A) Western Blotting analysis. HSP70 protein expression analysis derived from wild type cell lines (U266 and RPMI8226) and 
transduced cell lines (U266-LUC and RPMI8226-LUC). Densitometry analysis of protein bands. (B) U266 versus U266-LUC cell line. 
Graph of HSP70 protein relative expression was normalized with α/β tubulin. (C) RPMI8226 versus RPMI8226-LUC. Graph of HSP70 
protein relative expression was normalized with α/β tubulin. Bands were measured 3 times and represented in the graphs.
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Bortezomib used as single agent was able to induce 
late apoptosis in RPMI8226-LUC-PURO. On the other 
hand, U266-LUC-PURO presented a higher percentage of 
apoptosis when treated with bortezomib plus VER155008 
drug combination, overcoming the response to bortezomib 
alone. 
U266 cell line is recognized for being resistant to 
bortezomib [28], but combination of HSP70 inhibitor with 
bortezomib was able to overcome drug resistance and 
induced apoptosis, showing the synergistic effects of drug 
combination for U266-LUC-PURO: our study showed 
that bortezomib induced only 35% of cell death after 48 
hours of incubation; treatment with VER155008 (80 μM) 
induced more than 60% of cell death, and bortezomib plus 
VER155008 combination induced more than 70% of cell 
death. Zhang et al. (2013) [11] also demonstrated that 
treatment with VER155008 (80 μM) isolated for 24 hours 
resulted in higher percentage (60%) of cell death in U266 
cell line.
A possible explanation to different results in both 
cell lines relies on genetic background. RPMI8226 
presents t(14;16) translocation, TP53 point mutation 
[located in exon 7 (c.853G>A), resulting in a TP53 
missense mutation (p.E285K)], and no TP53 deletion by 
FISH [30]. U266 cell line has t(11;14), E419X missense 
mutation on RB1 and A161T missense mutation on TP53 
and also deletion of 17p [30, 31]. Therefore, U266-
LUC-PURO cell line presented better results with drug 
combination than with bortezomib alone, despite the high 
risk genetic profile, including noTP53 gene activity. 
VER155008 is an ATP competitive inhibitor 
and acts on HSPA1A/HSPA1B, HSPA5 and HSPA8 in a 
dose dependent manner [32]. Zhang et al. (2013) [11] 
tested VER155008 in four myeloma cell lines (U266, 
RPMI8226, H929 and KMS11), using concentrations 
between 5 to 80 µM, for 24 hours, and  showed that higher 
concentrations of VER155008 led to increased cell death 
rates. These results were confirmed by our group using 
RPMI8226 and U266 cell lines, since we observed higher 
cell death rates with 50 µM and 80 µM of VER155008, 
respectively. 
For our in vivo model #1, treatment with bortezomib, 
VER155008 or drug combination demonstrated reduced 
tumor growth after seven days with any of the drugs. This 
reduction in tumor growth was identified by decrease 
in bioluminescence, but not in tumor size, compared 
to control group (data not shown). Presumably, high 
sensitivity of BLI identifies active tumor areas versus 
necrotic areas (blue and purple signals in BLI) and tumor 
measurement does not take into consideration necrotic 
areas (Figure 4D and 4E). Mice RPMI8226-LUC-PURO 
tumors treated with bortezomib or VER155008, isolated or 
combined, presented decreased HSP70 protein expression; 
as expected, treatment with VER155008 alone led to 
a statistically significant protein expression reduction 
comparing to controls (p < 0.01). Increased expression of 
Beclin-1 in mice tumors treated with bortezomib, isolated 
or combined with VER155008, suggests that inhibition of 
the proteasome and/or HSP70 increases autophagy as a 
compensatory mechanism. Expression of XBP1-s (which is 
the functionally active transcription factor for UPR) in mice 
tumors treated with VER155008, isolated or combined 
with bortezomib, showed increased band intensity when 
compared to controls, also suggesting that UPR activity 
Figure 3: Relative expression of HSPA1A/HSPA1B, HSPA5, HSPA8, XBP-1 and Beclin-1 genes in bioluminescent cell 
lines. (A) RPMI8226-LUC-PURO untreated versus RPMI8226-LUC-PURO treated with bortezomib (100 nM) or VER155008 (50 µM 
or 80 µM) or bortezomib plus VER155008 (50 µM or 80 µM). (B) U266-LUC-PURO untreated versus U266-LUC-PURO treated with 
bortezomib or VER155008 (50 µM or 80 µM) or bortezomib plus VER155008 (50 µM or 80 µM). Relative expression was performed 
using 2-DDCt formula, with β-actin as housekeeping gene and untreated cell line as reference. One-Way ANOVA, with Bonferroni’s post -test.
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Figure 4: (A) Flow cytometry for late apoptosis detection (Annexin V/Propidium iodide) in RPMI8226-LUC-PURO untreated and treated 
cell line. (B) Flow cytometry for late apoptosis detection (Annexin V/Propidium iodide), in U266-LUC-PURO untreated and treated cell 
line. Analyzes performed 24 and 48 hours after incubation with bortezomib (100 nM) or VER155008 (50 μM or 80 μM) or bortezomib 
plus VER155008 (50 μM or 80 μM) (named as COMB50 µM or COMB80 µM) for both cell lines. X-axis: time, Y-axis: percentage of cells 
labeled with annexin V + and PI +. Experiments were performed in triplicates. Two-Way ANOVA, with Bonferroni’s post -test.
Figure 5: (A) Graph: BLI analysis of Nod.Cg-PrkdcscidII2rgtm-Gammanull mice. For this analysis, the highest value of bioluminescence 
acquired for each animal was chosen. (B) Histological tumor sample (H and E). Histologic sample obtained from RPMI8226-LUC-PURO 
tumor tissue of untreated mouse (100 ×). (C) Immunohistochemical analysis of the histologic tumor sample. RPMI8226-LUC-PURO tumor 
tissue of untreated mouse (lambda positive) (400 ×). (D) Histological tumor sample (H and E). RPMI8226-LUC-PURO tumor tissue from 
mouse treated with bortezomib plus VER155008 showing tumor coagulative necrosis area and apoptotic cells (400×). (E) Histological 
tumor sample (H&E). The same image above with magnification 100 ×, showing tumor coagulative necrosis area (arrow) and apoptotic 
cells.
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was used to avoid ER stress due to impairment of related 
pathways involved in protein homeostasis. 
In our in vivo model #2, we treated mice at the same 
time when cell lines were transplanted. With this strategy, 
treatment with drugs alone (especially VER155008) or in 
combination (VER155008 and bortezomib) demonstrated 
significant impact in preventing tumor growth for 
both RPMI8226-LUC-PURO and U266-LUC-PURO, 
compared to the untreated group. 
In conclusion, our study showed that the combination 
of proteasome and HSP70 inhibitors induced cell death in 
tumor cells, with particular relevant results in U266 cell 
line, which presents high risk genetic profile. Since HSP70 
connects multiple signaling pathways, it works synergistically 
to protect tumor cells from death by proteotoxic stress, and 
can represent a key role to establish a new approach for high 
risk MM treatment, especially after achievement of the best 
therapeutic response, or as maintenance therapy. 
MATERIALS AND METHODS 
Ethical aspects
 The present study was approved by the Federal 
University of São Paulo Ethical Committee (CEP/CEUA 
0219/2012). 
Cell lines
 MM cell lines RPMI8226 and U266 were 
maintained in culture medium (RPMI-1640 
supplemented with 10% fetal bovine serum, 1% 
L-glutamine, 1% NEAA [non essentials amino acids] 
– Gibco Laboratory, Grand Island, NY, USA – and 
garamicine), at 37ºC with 5% CO2. 
Lentiviral transduction
1 × 106 RPMI8226 and U266 cells were transduced 
with a luciferase expression vector (p-Lenti PGK V5-
LUC Puro, Firefly luciferase, Addgene, Cambridge, 
MA, USA) at a multiplicity of infection of 0.5 in 600 
µL of RPMI 1640 culture medium with L-glutamine 
(Life Technologies, Carlsbad, CA, USA), supplemented 
with fetal bovine serum (10%), NEAA and 8μg/mL of 
Polibrene (Sigma Aldrich Co., St Louis, MO, USA). 
Medium with viral particles was replaced after 8 hours and 
cells were maintained in culture for 3 weeks in the same 
culture medium plus 2 μg/mL of puromycin (selecting 
permanent expression of transduced genes). After this 
step, the bioluminescent cells were named RPMI8226-
LUC-PURO and U266-LUC-PURO. 
Figure 6: (A) Western blotting analysis. HSP70, Beclin-1 and XBP-1s protein expression analysis derived from tumor tissue of untreated 
Nod.Cg-PrkdcscidII2rgtm-Gammanull mice and mice treated with either bortezomib (1 mg/kg) or VER155008 (40 mg/kg), alone or in 
combination, for one week (n = 4 in each group). Densitometry analysis of protein bands. (B) Graph of HSP70 protein relative expression 
normalized with α/β tubulin, calculated using four replicates. (C) Graph of Beclin-1 protein relative expression normalized with α/β 




 RNA was extracted from MM cell lines using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), 
following the manufacturer’s instructions. RNA was 
purified with phenol and chloroform and its integrity was 
evaluated by 1% agarose gel electrophoresis. 
RNA quantification and cDNA synthesis
RNA was quantified by DS-11 spectrophotometer 
(Denovix, Thermo, Rockford, IL, USA). 25µg of RNA 
were treated with RQ1 DNase (Promega Corporation, 
Madison, WI, USA), following manufacturer’s 
instructions. 2 µg of total RNA were reverse transcribed 
with SuperScript III (Invitrogen, Carlsbad, CA, USA), 
according to manufacturer’s instructions. 
Real time quantitative PCR (qPCR)
Gene expression analyses were performed in 
RPMI8226-LUC-PURO and U266-LUC-PURO cell lines, 
with or without treatment with bortezomib (100 nM) or 
VER155008 (in two concentrations 50 µM or 80 µM), 
isolated or combined, using the 7500 Real Time PCR 
System (Applied Biosystems, Foster City, CA, USA). 
β-actin was used as housekeeping gene for HSP70 family 
members (Hs00271244_s1 for HSPA1B and HSPA1A; 
HS00607129_gh for HSPA5 and Hs03044880_gh for 
HSPA8), autophagy and UPR related genes (Hs00186838_
m1 for Beclin-1(BECN1) and Hs00231936_m1 for XBP-1, 
respectively) (for all genes, Life Technologies, Carlsbad, 
CA, USA). Relative gene expression was calculated using 
the equation 2-DDCt [21].
Figure 7: (A–D). BLI analysis of Nod.Cg-PrkdcscidII2rgtm-Gammanull mice xenotransplanted with RPMI8226-LUC-PURO cell line 
(left flank) and U266-LUC-PURO cell line (right flank) treated with either bortezomib (1 mg/kg) or VER155008 (40 mg/kg), alone or in 
combination, for one week (n = 3 in each group). (A) Control group consisted of mice with no intervention. (B) Treatment with bortezomib. 
(C) Treatment with VER155008. (D) Treatment with bortezomib with VER155008. Evaluations were performed 24, 72, 120, 168 and 
192 hours after treatment (triplicate analyzes were performed). BLI acquisition was performed using IVIS Kinetic equipment. (Two-way 
ANOVA with Bonferroni post- test). 
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Apoptosis analyses
For apoptosis assays, bortezomib (100nM) 
and VER155008 (50 µM or 80 µM) [11] (both from 
Selleckchem, Huston, TX, USA) were used in the 
bioluminescent cell lines (1 × 105 RPMI8226-LUC-
PURO and U266-LUC-PURO), isolated or combined. 
Cells were analyzed in triplicate after 24 and 48 hours 
of treatment. Two controls were used: cells without any 
drug treatment and treated with DMSO (drug diluent, 
for both drugs bortezomib and VER155008). Cells were 
labeled with annexin V and/or propidium iodide (PI) 
(Becton Dickinson, Franklin Lakes, NJ, USA), according 
to manufacturer’s instructions.Fluorescence intensity 
was evaluated with the cytometer FACSCalibur (BD 
Biosciences, Franklin Lakes, NJ, USA). 
Xenograft model #1: tumor growth reduction
NOD.Cg-PrkdcscidII2rgtm-Gammanull female mice 
(n = 16) (6-to-8-week age) were inoculated subcutaneously 
into the right flank with 1 × 106 RPMI8226-LUC-
PURO cells together with 200 µL of matrigel basement 
membrane matrix (BD Bioscience, Bedford, MA). When 
tumor achieved between 50 mm3 to 80 mm3 in diameter, 
mice were randomized into four treatment groups (n 
= 4 in each group), receiving intravenous bortezomib 
(1 mg/kg), or VER155008 (40 mg/kg), or bortezomib 
plus VER155008 combination [22]. The control group 
consisted of mice without intervention. Mice were treated 
for one week, being VER155008 administered as a single 
dose and bortezomib given twice a week. Evaluations were 
performed before treatment (point 0), after 72 hours and 
after one week of treatment. Bioluminescence acquisition 
(total flux, fotons/s) was performed by the IVIS Kinetic 
equipment (triplicate analyses were performed for each 
animal) [23, 24]. Each photon is represented by a number 
equivalent to its intensity. A color is associated with each 
numeric value and a color scale is created. The amount of 
light emitted was evaluated in photons/second (photons/s). 
The photon measurement represents a calibrated unit of 
photon emission through the sample and is used to quantify 
bioluminescence according to the Living Image Software 
User´s Manual (Capiler Life Science, Hopkinton, MA, 
USA). Mice received intraperitoneal luciferin injection 
(150 mg/kg) 10 minutes before the procedure and after 
Figure 8: The graphs correspond to the measurement of bioluminescence in Nod.Cg-PrkdcscidII2rgtm-Gammanull 
mice treated with VER155008 (40 mg/kg) or bortezomib (1 mg/kg), alone or in combination, for one week. (A) BLI 
analysis of PrkdcscidII2rgtm-Gammanull mice related to RPMI8226-LUC-PURO cells xenograft (n = 3). Mice treated with VER155008 
(40 mg/kg) or treated with bortezomib (1 mg/kg) plus VER155008 showed reduction in bioluminescence comparing to control group (p 
< 0.001), while treatment with bortezomib showed reduction in bioluminescence only after seven days of evaluation (p < 0.05). (B) BLI 
analysis of PrkdcscidII2rgtm-Gammanull mice related to U266-LUC-PURO cells xenograft (n = 3). Mice treated with VER155008 (40 mg/
kg) or treated with bortezomib (1 mg/kg) plus VER155008 showed reduction in bioluminescence comparing to control group (p < 0.001), 
while treatment with bortezomib showed reduction in bioluminescence only after seven days of evaluation (p < 0.05).
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isoflurane anesthesia (1 mg/kg) [25–27]. Tumors were 
resected and frozen at –80oC for further protein extraction. 
Tumor specimens were also analyzed in microscope after 
hematoxylin/ eosin and light chain stains.
Xenograft model #2: tumor growth inhibition
NOD.Cg-PrkdcscidII2rgtm-Gammanull female mice 
(n = 12) (6-to-8-week age) (divided into four treatment 
groups, containing 3 mice each), were treated immediately 
after transplant of the cell lines together with 200µL of 
matrigel basement membrane matrix (U266-LUC-PURO 
on the right flank and RPMI8226-LUC-PURO on the 
left flank). Treatment was performed in the same way 
described for model #1. Control group consisted of mice 
without intervention. Evaluations were performed 24, 72, 
120, 168 and 192 hours after treatment. The acquisition 
of bioluminescence was performed in the same way 
described for model #1.
Western blotting
Proteins were extracted from cell lines or frozen 
tumors (–80°C) using the Total Protein extraction kit (RF-
2140) (EDM-Millipore, Darmstadt, Germany) according 
to manufacturer’s recommendations. Protein quantification 
was performed with DS-11 spectrophotometer (Denovix, 
Thermo, Rockford, IL, USA), using the Bradford method. 
20 µg (cell lines) or 10 µg (tumors) of protein were used 
in 1% polyacrylamide gel electrophoresis containing 
sodium dodecyl sulfate (SDS-PAGE) for band separation. 
After electrophoresis, proteins were transferred to a 
polyvinylidene fluoride (PVDF) membrane (Amersham 
Hybond-P, GE Healthcare, Buckinghamshire, UK). 
Next, membranes were incubated overnight at 4ºC with 
anti-HSP70 (HSP70 antibody detects endogenous levels 
of total HSP70 protein and HSC70), anti-XBP-1s, anti-
Beclin-1 or anti-α/β (control) primary antibody (Cell 
Signaling, Danvers, MA, USA) (dilution - 1:1000). 
After incubation with secondary antibody, Immobilion 
Western Chemiluminescent HRP Substrate (Millipore, 
Darmstadt, Germany) was used in the proportion of 
1:1 to highlight protein presence. The membrane was 
visualized on an UVITEC Cambridge equipment (UVItec 
Limited, Cambridge, UK) with chemiluminescence filter. 
Densitometric analysis was performed to quantify bands 
volume using UVITEC BAND software (UVItec Limited, 
Cambridge, UK). The ratios were calculated using the 
respective α/β-tubulin bands as normalizers.
Statistical analysis
Gene expression in luciferase transduced cell 
lines was analyzed with One-Way ANOVA, followed by 
Bonferroni’s post-test. The other comparisons between the 
different treatment groups (in vitro and in vivo studies), 
over time, were performed with Two-way ANOVA 
test, and Bonferroni post-test, using Graphpad Prism 5 
software. Values of p < 0.05 were considered significant. 
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